help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jay, P. R.
Right arrow Articles by Horowitz, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jay, P. R.
Right arrow Articles by Horowitz, M. C.

Endocrinology, Vol 137, 1151-1158, Copyright © 1996 by Endocrine Society

ARTICLES

Oncostatin-M: a new bone active cytokine that activates osteoblasts and inhibits bone resorption

PR Jay, M Centrella, J Lorenzo, AG Bruce and MC Horowitz
Department of Orthopaedics, Yale University School of Medicine, New Haven, Connecticut 06520-8071, USA.

Osteoblasts and their precursors respond to specific cytokines, growth factors, and hormones. One facet of this response includes the secretion of additional cytokines, some of which are part of the circuitry involved in the regulation of osteoblast and osteoclast function. Therefore, understanding which cytokines are able to activate osteoblastic cells and the consequences of that activation are central to understanding normal and pathologic bone remodeling. Oncostatin M (OSM) is a glycoprotein belonging to a new subfamily of cytokines related by sequence and structural homology and the use of the signal transducing receptor component gp130. Osteoblastic cells secrete and respond to leukemia-inhibiting factor (LIF) both in vitro and in vivo, suggesting that LIF is an autocrine regulatory factor. OSM is closely related to LIF, and therefore we hypothesized that OSM should regulate the function of cells in the osteoblastic lineage. Primary neonatal murine or fetal rat calvarial osteoblastic cultures were treated with OSM or LIF and a series of biochemical and biological parameters were determined. In these cultures, OSM induced proliferation, collagen synthesis, and interleukin-6 secretion, whereas it inhibited alkaline phosphatase activity. Bone resorption was also inhibited by OSM. These data represent the first report of OSM's effects on bone cell function and indicate that, like some other members of the LIF/interleukin-6 subfamily, OSM has potent bone regulatory activity.


This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
J. Lorenzo, M. Horowitz, and Y. Choi
Osteoimmunology: Interactions of the Bone and Immune System
Endocr. Rev., June 1, 2008; 29(4): 403 - 440.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. Palmqvist, E. Persson, H. H. Conaway, and U. H. Lerner
IL-6, Leukemia Inhibitory Factor, and Oncostatin M Stimulate Bone Resorption and Regulate the Expression of Receptor Activator of NF-{kappa}B Ligand, Osteoprotegerin, and Receptor Activator of NF-{kappa}B in Mouse Calvariae
J. Immunol., September 15, 2002; 169(6): 3353 - 3362.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
A. S. K. de Hooge, F. A. J. van de Loo, M. B. Bennink, D. S. de Jong, O. J. Arntz, E. Lubberts, C. D. Richards, and W. B. van den Berg
Adenoviral Transfer of Murine Oncostatin M Elicits Periosteal Bone Apposition in Knee Joints of Mice, Despite Synovial Inflammation and Up-Regulated Expression of Interleukin-6 and Receptor Activator of Nuclear Factor-{kappa}B Ligand
Am. J. Pathol., May 1, 2002; 160(5): 1733 - 1743.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
A F Wahl and P M Wallace
Oncostatin M in the anti-inflammatory response
Ann Rheum Dis, November 1, 2001; 60(90003): iii75 - 80.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. J. Auernhammer and S. Melmed
Leukemia-Inhibitory Factor--Neuroimmune Modulator of Endocrine Function
Endocr. Rev., June 1, 2000; 21(3): 313 - 345.
[Abstract] [Full Text]

Home page
 Stem CellsHome page
R. A. Gadient and P. H. Patterson
Leukemia Inhibitory Factor, Interleukin 6, and Other Cytokines Using the GP130 Transducing Receptor: Roles in Inflammation and Injury
Stem Cells, May 1, 1999; 17(3): 127 - 137.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
T. Thomas, F. Gori, S. Khosla, M. D. Jensen, B. Burguera, and B. L. Riggs
Leptin Acts on Human Marrow Stromal Cells to Enhance Differentiation to Osteoblasts and to Inhibit Differentiation to Adipocytes
Endocrinology, April 1, 1999; 140(4): 1630 - 1638.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. Varghese, K. Yu, and E. Canalis
Leukemia inhibitory factor and oncostatin M stimulate collagenase-3 expression in osteoblasts
Am J Physiol Endocrinol Metab, March 1, 1999; 276(3): E465 - E471.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
N. Franchimont, V. Gangji, D. Durant, and E. Canalis
Interleukin-6 with Its Soluble Receptor Enhances the Expression of Insulin-Like Growth Factor-I in Osteoblasts
Endocrinology, December 1, 1997; 138(12): 5248 - 5255.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
K. Kawasaki, Y.-H. Gao, S. Yokose, Y. Kaji, T. Nakamura, T. Suda, K. Yoshida, T. Taga, T. Kishimoto, H. Kataoka, et al.
Osteoclasts Are Present in gp130-Deficient Mice
Endocrinology, November 1, 1997; 138(11): 4959 - 4965.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1996 by The Endocrine Society